Sabine Kühn

University of Würzburg — Germany

Medicine · Health Sciences

18h-index972citations79works1.92yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(20), Chemokine receptors and signaling(16), HER2/EGFR in Cancer Research(12), Immunotherapy and Immune Responses(10), Cancer Immunotherapy and Biomarkers(7)

Publications79 total

LA NIÑA severa and its impact on soybean seed yield and quality

2 cited

Agronomy Science and Biotechnology·2025· 2 citedOpen Access

TLR2-induced surface mobilization and release of CD14 in human platelets

Scientific Reports·2025Open Access

A fully human In-vitro model for bone metastasis: potential of an electrospun scaffold as alternative to biological materials for osteoblast/osteoclast differentiation

2 cited

Materialia·2025· 2 citedOpen Access

Erfolgreiche Etablierung eines Praktikums für Transfusionsmedizin – das Projekt TIMMY (Transfusionsmedizin-Training mit Dummys)

Transfusionsmedizin·2025

A Multicellular In Vitro Model of the Human Intestine with Immunocompetent Features Highlights Host‐Pathogen Interactions During Early Salmonella Typhimurium Infection

5 cited

Advanced Science·2025· 5 citedOpen Access

Effect of toxins from different periodontitis‐associated bacteria on human platelet function

1 cited

Molecular Oral Microbiology·2024· 1 citedOpen Access

Influence of short-term refrigeration on collagen-dependent signalling mechanisms in stored platelets

3 cited

Cellular Signalling·2024· 3 citedOpen Access

TOWARDS DAILY ONLINE MR-IMAGE-GUIDED PARTICLE THERAPY: FIRST CLINICAL APPLICATION OF A SHUTTLE-BASED WORKFLOW AT THE HEIDELBERG ION-BEAM THERAPY CENTER

2 cited

International Journal of Particle Therapy·2024· 2 citedOpen Access

Composition of plasma in apheresis-derived platelet concentrates under cold storage.

4 cited

PubMed·2023· 4 citedOpen Access

Table S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S3 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S3 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S6 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S2 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S5 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S7 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S1 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Figure S4 from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

Data from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer In Vitro and In Vivo

2023Open Access

page 1 of 4Next →

Frequent Co-authors

Juergen Koessler(12), Anna Kobsar(11), Angela Koessler(11), Franca Ronchese(9), Markus Boeck(9), Katja Weber(7), Jianping Yang(5), Evelyn Hyde(5), Jürgen Debus(4), Jacquie L. Harper(4), Marius Niklaus(4), Jürgen Ruland(3), Joanna R. Kirman(3), Evelyn Putz(3), Erdwine Klinker(3), Julia Zeller‐Hahn(3), Reiner Schroll(2), Fenella J. Rich(2), Klaus Herfarth(2), Holger Hof(2)